Compare MEC & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MEC | ANNX |
|---|---|---|
| Founded | 1945 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 345.2M | 334.1M |
| IPO Year | 2019 | 2020 |
| Metric | MEC | ANNX |
|---|---|---|
| Price | $18.52 | $4.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $22.00 | $16.60 |
| AVG Volume (30 Days) | 216.0K | ★ 3.6M |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $533,523,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.73 | N/A |
| P/E Ratio | $31.71 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.72 | $1.29 |
| 52 Week High | $19.25 | $5.66 |
| Indicator | MEC | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 65.49 | 69.84 |
| Support Level | $16.81 | $4.01 |
| Resistance Level | $19.25 | $5.34 |
| Average True Range (ATR) | 0.79 | 0.28 |
| MACD | 0.21 | 0.03 |
| Stochastic Oscillator | 79.94 | 68.80 |
Mayville Engineering Co Inc is involved in a manufacturing partner providing a full suite of manufacturing solutions from concept to production, including design, prototyping and tooling, fabrication, aluminum extrusion, coating, assembly and aftermarket components. Its customers operate in diverse end markets, including heavy- and medium-duty commercial vehicles, construction, power sports, agriculture, military, and other end markets. Its services comprise stamping, shearing, fiber laser cutting, forming, drilling, tapping, grinding, tube bending, machining, welding, assembly and logistic services.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.